Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Digoxin for Reinduction of Radioiodine Uptake in Thyroid Carcinoma
NCT05507775Completed
- Sponsor
- Radboud University Medical Center
- Start
- Dec 2022
- Primary completion
- Jun 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Open-label, single-arm trial of digoxin in thyroid carcinoma (TC), sponsored by Radboud University Medical Center. Primary endpoint: Reinduction of radioiodine uptake in target lesion at 3 weeks. Started Dec 2022; status: completed.
02
Drugs
digoxin
03
Conditions
thyroid carcinoma (TC)
Beyond the preview
Go deeper on NCT05507775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05507775.